Neuland Laboratories Limited

BSE:524558 Stock Report

Market Cap: ₹236.4b

Neuland Laboratories Future Growth

Future criteria checks 5/6

Neuland Laboratories is forecast to grow earnings and revenue by 23.8% and 15.6% per annum respectively. EPS is expected to grow by 23.6% per annum. Return on equity is forecast to be 22.8% in 3 years.

Key information

23.8%

Earnings growth rate

23.61%

EPS growth rate

Pharmaceuticals earnings growth16.2%
Revenue growth rate15.6%
Future return on equity22.77%
Analyst coverage

Low

Last updated07 Jul 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 13

524558: New Leadership And Transdermal CDMO Work Will Support Future Upside Potential

Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹20,972, with only marginal tweaks to long term growth, profit margin and future P/E assumptions. As a result, the overall price target remains unchanged.
Narrative Update • May 30

524558: New CEO And CDMO Focus Will Support Future Upside Potential

Analysts now peg Neuland Laboratories' fair value at ₹20,972, compared with the previous ₹18,852.75, citing updates to long term revenue growth, profit margin assumptions, and a higher future P/E multiple in their models. What's in the News A board meeting is scheduled for May 12, 2026 at 14:15 IST to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for FY 2025-26, along with other matters (Key Developments).
Narrative Update • May 12

524558: Leadership Transition And CDMO Focus Will Shape Balanced Future Potential

Analysts have trimmed their fair value estimate for Neuland Laboratories slightly from ₹18,865.25 to ₹18,852.75. This reflects small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E multiples.
Narrative Update • Apr 20

524558: Leadership Transition And Peptide Collaboration Will Support Future Upside Potential

Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25, reflecting unchanged views on discount rate, revenue growth, profit margin, and future P/E assumptions that underpin their price target rationale. What's in the News Neuland Laboratories plans a leadership transition, with Saharsh Davuluri set to become Chief Executive Officer from 01 April 2026.
Narrative Update • Apr 04

524558: Phase 2 Peptide Design Progress Will Support Future Upside Potential

Analysts have maintained their price target for Neuland Laboratories at ₹18,865.25, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. This signals that the latest review did not alter their core outlook on the stock.
Narrative Update • Mar 20

524558: Phase 2 Peptide Progress And 2026 Board Meeting Will Support Upside Potential

Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25. This reflects unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E expectations.
Narrative Update • Mar 05

524558: Peptide Partnership Progress And Upcoming Results Date Will Support Future Upside Potential

Analysts have maintained their fair value estimate for Neuland Laboratories at ₹18,865.25 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. As a result, this narrative update focuses on reaffirmed conviction rather than a change in the price target.
Narrative Update • Feb 19

524558: New R&D Center And Peptide Partnership Will Support Future Upside Potential

Analysts have revised their price target for Neuland Laboratories from ₹20,659 to ₹18,865, reflecting updates to their model that now factors in adjusted assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News LIR Life Sciences has started Project Phase 2 peptide design work with Neuland Laboratories, focusing on next generation cell penetrating peptides for its transdermal delivery platform, following completion of Phase 1 synthesis work (Product related announcement).
Narrative Update • Feb 05

524558: New R&D Center Will Support Future Upside Potential

Analysts have kept their price target for Neuland Laboratories unchanged at ₹20,659, citing consistent assumptions on discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Board meeting scheduled for February 9, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).
Narrative Update • Jan 21

524558: New R&D Center And Peptide Partnership Will Drive Future Upside

Analysts have trimmed their fair value estimate for Neuland Laboratories from ₹20,884 to ₹20,659, citing slightly adjusted views on revenue growth, profit margins and future P/E assumptions while keeping the discount rate unchanged. What's in the News LIR Life Sciences Corp.
Narrative Update • Jan 06

524558: New R&D Center Capex Will Support Future Upside Potential

Analysts have kept their fair value estimate for Neuland Laboratories unchanged at ₹20,884. This steady view is supported by consistent assumptions on discount rate, revenue growth, profit margin and future P/E.
Narrative Update • Dec 15

524558: New R&D Center Will Drive Future Upside Potential

Narrative Update on Neuland Laboratories Analysts have modestly revised their price target on Neuland Laboratories with a slight adjustment that reflects largely unchanged assumptions around fair value at ₹20,884, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News The board will consider capital expenditure of INR 1,890 million for establishing a new Research and Development Center at the meeting scheduled on November 28, 2025 (Board Meeting).
Narrative Update • Dec 01

524558: R&D Center and Leadership Changes Will Unlock Upside Potential

Analysts have maintained their price target for Neuland Laboratories at ₹20,884, citing consistent estimates for future revenue growth and profit margin projections. What's in the News A Board Meeting is scheduled for November 28, 2025 to approve and consider a capital expenditure of INR 1,890 million for setting up a Research & Development (R&D) Center.
Narrative Update • Nov 17

524558: Executive Leadership Changes Will Drive Future Upside Potential

Analysts have raised their fair value estimate for Neuland Laboratories from ₹17,494.50 to ₹20,884.00. They cite updated assumptions about growth and profitability, despite modest adjustments to revenue growth and profit margin forecasts.
Narrative Update • Nov 03

524558: Leadership Changes And Board Decisions Will Shape The Next Phase

Analysts have raised their price target for Neuland Laboratories from ₹16,375 to ₹17,494.50. This change reflects updated expectations based on modest adjustments in forecasted revenue growth, profit margin, and valuation multiples.
Narrative Update • Sep 05

Manufacturing Expansion And Peptide Expertise Will Unlock Future Opportunities

Neuland Laboratories’ target price has been revised upward as a result of a marked increase in its forecast P/E ratio despite a significant decline in net profit margin, now reflecting a new consensus of ₹16,375. What's in the News Special/Extraordinary Shareholders Meeting to be conducted via postal ballot.
User avatar
New Narrative • Feb 24

Ongoing Capacity Expansions In CDMO And Specialty GDS Set To Strengthen Future Prospects

New facilities and capacity expansion will drive revenue growth and improve operational efficiency by FY '26.

Earnings and Revenue Growth Forecasts

BSE:524558 - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202933,148N/AN/AN/A1
3/31/202827,7985,8063,7016,1464
3/31/202723,0884,2094,0175,8664
3/31/202620,2303,640-5053,467N/A
12/31/202515,7511,791N/AN/AN/A
9/30/202515,3342,401-1,4251,312N/A
6/30/202513,3001,761N/AN/AN/A
3/31/202514,7682,6011,1093,174N/A
12/31/202415,3352,999N/AN/AN/A
9/30/202415,2832,7974132,457N/A
6/30/202416,3523,361N/AN/AN/A
3/31/202415,5863,0011,1752,612N/A
12/31/202315,8093,171N/AN/AN/A
9/30/202314,5742,6622,4443,192N/A
6/30/202313,3332,154N/AN/AN/A
3/31/202311,9151,6351,7112,372N/A
12/31/202210,4061,008N/AN/AN/A
9/30/202210,0788313411,070N/A
6/30/20229,720651N/AN/AN/A
3/31/20229,517638-373604N/A
12/31/20219,400593N/AN/AN/A
9/30/20219,4897313591,437N/A
6/30/20219,324742N/AN/AN/A
3/31/20219,3708068401,894N/A
12/31/20208,852540N/AN/AN/A
9/30/20208,43638496887N/A
6/30/20207,884257N/AN/AN/A
3/31/20207,64016285573N/A
12/31/20197,443321N/AN/AN/A
9/30/20197,120257N/A899N/A
6/30/20196,945216N/AN/AN/A
3/31/20196,675164N/A699N/A
3/31/20185,284121N/A113N/A
3/31/20175,789469N/A387N/A
3/31/20165,100273N/A448N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524558's forecast earnings growth (23.8% per year) is above the savings rate (6.9%).

Earnings vs Market: 524558's earnings (23.8% per year) are forecast to grow faster than the Indian market (16.3% per year).

High Growth Earnings: 524558's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 524558's revenue (15.6% per year) is forecast to grow faster than the Indian market (11.1% per year).

High Growth Revenue: 524558's revenue (15.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 524558's Return on Equity is forecast to be high in 3 years time (22.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 15:26
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neuland Laboratories Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit Bhat360 ONE Capital Market Private Limited
Srivathsan RamachandranAvendus Spark
Kameswari V. S. ChavaliFirstCall Research